INVE-B Stock Analysis: Investor ser. | ST

Asset Management | ST, Sweden | Market Cap: 1.303.764m SEK | 12M Return: 32.4% | SE0015811963 | Charts, Fundamentals & Technical Analysis

Healthcare, Financial Services, Information Technology, Life Sciences
Total Rating 63
Safety 71
Buy Signal -0.04
Environmental & Facilities Services
Sub-Industry Rotation: +9.9
Market Cap: 128B
Avg Turnover: 1.08B
Risk 3d forecast
Volatility28.7%
VaR 5th Pctl5.15%
VaR vs Median8.71%
Reward TTM
Sharpe Ratio1.57
Rel. Str. IBD80.2
Rel. Str. Peer Group81.3 pctl
Character TTM
Beta0.537
Beta Downside0.361
Hurst Exponent0.566
Choppyness43.3%
Drawdowns 3y
Max DD22.04%
CAGR/Max DD1.19
CAGR/Mean DD7.15
EPS (Earnings per Share) EPS (Earnings per Share) of INVE-B over the last years for every Quarter: "2021-09": 8.8033, "2021-12": 26.46, "2022-03": -22.5527, "2022-06": -21.38, "2022-09": 2.7334, "2022-12": 16.81, "2023-03": 10.7237, "2023-06": 14.8058, "2023-09": -3.621, "2023-12": 19.56, "2024-03": 21.87, "2024-06": 21.27, "2024-09": 4.1787, "2024-12": -10.35, "2025-03": -0.9898, "2025-06": 14.78, "2025-09": 19.52, "2025-12": 18.07, "2026-03": 9.82, "2026-06": 38.26, "2026-09": 3.8881,
EPS CAGR: 10.52%
EPS Trend: 12.4%
Qual. Beats: 0
Revenue Revenue of INVE-B over the last years for every Quarter: 2021-09: 37657, 2021-12: 92153, 2022-03: -57362, 2022-06: -51916, 2022-09: 22447, 2022-12: 65661, 2023-03: 46457, 2023-06: 61241, 2023-09: 2442, 2023-12: 74711, 2024-03: 82210, 2024-06: 80866, 2024-09: 26774, 2024-12: -13955, 2025-03: 11905, 2025-06: 61579, 2025-09: 75355, 2025-12: 72988, 2026-03: 25923, 2026-06: 133926, 2026-09: 19900,
Rev. CAGR: 6.41%
Rev. Trend: 14.4%
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 11.9 years of data, until 10/2026

Jan +0.9% 21
Feb -0.0% 0
Mar -0.8% 4
Apr +1.0% 14
May +0.2% 4
Jun -1.7% 28
Jul +2.5% 28
Aug -2.8% 28
Sep -1.5% 4
Oct +0.3% 0
Nov +0.2% 21
Dec -2.1% 21

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: INVE-B Investor ser.

Investor AB (publ) is a Swedish investment company founded in 1916 and headquartered in Stockholm, operating as both a private equity firm and a long-term strategic holding company. The firm manages two main investment streams: core investments focused on sectors such as health care, financial services, IT, fintech, life sciences, AI, and quantum technology through minority positions in listed companies; and operating investments targeting medium to large companies primarily headquartered in Northern Europe, with ticket sizes generally between $200 million and $700 million. Investor AB typically holds controlling interests or significant minority stakes in its operating investments, often seeking board representation, while financial investments are held as smaller minority positions over shorter horizons. Private equity holdings are usually held for three to seven years before exit.

Listed on the Stockholm Stock Exchange, Investor AB is controlled by the Wallenberg family through their holding entities, which is characteristic of several large Swedish industrial holding companies. The firms dual structure of long-term core holdings paired with more active operating and financial investments distinguishes it from traditional private equity firms, as core positions are intended to be held indefinitely to support strategic development across industrial, technological, and financial sectors.

Headlines to Watch Out For
  • Atlas Copco and ABB valuations lift portfolio NAV
  • Private equity exits accelerate capital recycling into new investments
  • Swedish krona weakness pressures reported earnings translation
Piotroski VR-10 (Strict) 6.5
Net Income: 215b TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.07 > 1.0
NWC/Revenue: 6.53% < 20% (prev 19.74%; Δ -13.21% < -1%)
CFO/TA 0.02 > 3% & CFO 26.5b > Net Income 215b
Net Debt (111b) to EBITDA (220b): 0.50 < 3
Current Ratio: 1.84 > 1.5 & < 3
Outstanding Shares: last quarter (3.06b) vs 12m ago -0.05% < -2%
Gross Margin: 91.85% > 18% (prev 88.36%; Δ 3.49% > 0.5%)
Asset Turnover: 21.81% > 50% (prev 12.81%; Δ 9.00% > 0%)
Interest Coverage Ratio: 38.02 > 6 (EBIT TTM 220b / Interest Expense TTM 5.78b)
Altman Z'' 10.00
A: 0.01 (Total Current Assets 36.2b - Total Current Liabilities 19.7b) / Total Assets 1265b
B: 0.73 (Retained Earnings 925b / Total Assets 1265b)
C: 0.19 (EBIT TTM 220b / Avg Total Assets 1159b)
D: 6.64 (Book Value of Equity 1099b / Total Liabilities 165b)
Altman-Z'' = 10.72 = AAA
Beneish M -2.52
DSRI: 0.86 (Receivables 19.6b/12.1b, Revenue 253b/135b)
GMI: 0.96 (GM 88.36% / 91.85%)
AQI: 1.02 (AQ_t 0.95 / AQ_t-1 0.94)
SGI: 1.87 (Revenue 253b / 135b)
TATA: 0.15 (NI 215b - CFO 26.5b) / TA 1265b)
Beneish M = -2.52 (Cap -4..+1) = A
What is the price of INVE-B shares?

As of November 22, 2026, the stock is trading at SEK 408.25 with a total of 4,719,401 shares traded. Over the past week, the price has changed by -6.42%, over one month by -0.95%, over three months by -0.07% and over the past year by +32.37%.

Current recommended Stop Loss: 399.60 (which is 2.1% or 1.4 ATR below the current price).

Is INVE-B a buy, sell or hold?

Investor ser. has no consensus analysts rating.

Investor ser. (INVE-B) - Fundamental Data Overview as of 18 November 2026
Market Cap USD = 128b (1304b SEK * 0.0978 SEK.USD)
P/E Trailing = 6.0758
P/E Forward = 3.7707
P/S = 4.6168
P/B = 1.2161
P/EG = 5.0848
Revenue TTM = 253b SEK
EBIT TTM = 220b SEK
EBITDA TTM = 220b SEK
Long Term Debt = 111b SEK (from longTermDebt, last fiscal year)
Short Term Debt = 1.43b SEK (from shortTermDebt, last quarter)
Debt = 127b SEK (from shortLongTermDebtTotal, last quarter) + Leases 128.0m
Net Debt = 111b SEK (calculated: Debt 127b - CCE 16.7b)
Enterprise Value = 1414b SEK (1304b + Debt 127b - CCE 16.7b)
Interest Coverage Ratio = 38.02 (Ebit TTM 220b / Interest Expense TTM 5.78b)
EV/FCF = 61.33x (Enterprise Value 1414b / FCF TTM 23.1b)
FCF Yield = 1.63% (FCF TTM 23.1b / Enterprise Value 1414b)
FCF Margin = 9.13% (FCF TTM 23.1b / Revenue TTM 253b)
Net Margin = 84.96% (Net Income TTM 215b / Revenue TTM 253b)
Gross Margin = 91.85% ((Revenue TTM 253b - Cost of Revenue TTM 20.6b) / Revenue TTM)
Gross Margin QoQ = 53.31% (prev none%)
Tobins Q-Ratio = 1.12 (Enterprise Value 1414b / Total Assets 1265b)
Interest Expense / Debt = 4.54% (Interest Expense 5.78b / Debt 127b)
Taxrate = 0.75% (1.62b / 216b)
NOPAT = 218b (EBIT 220b * (1 - 0.75%))
Current Ratio = 1.84 (Total Current Assets 36.2b / Total Current Liabilities 19.7b)
Debt / Equity = 0.12 (Debt 127b / totalStockholderEquity, last quarter 1099b)
Debt / EBITDA = 0.50 (Net Debt 111b / EBITDA 220b)
Debt / FCF = 4.80 (Net Debt 111b / FCF TTM 23.1b)
Total Stockholder Equity = 1031b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.53% (Net Income 215b / Total Assets 1265b)
RoE = 20.83% (Net Income TTM 215b / Total Stockholder Equity 1031b)
RoCE = 19.25% (EBIT 220b / Capital Employed (Equity 1031b + L.T.Debt 111b))
RoIC = 17.42% (NOPAT 218b / Invested Capital 1252b)
WACC = 7.19% (E(1304b)/V(1431b) * Re(7.45%) + D(127b)/V(1431b) * Rd(4.54%) * (1-Tc(0.01)))
Discount Rate = 7.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 44.56 | Cagr: -0.03%
[DCF] Terminal Value 77.97% ; FCFF base≈21.2b ; Y1≈24.3b ; Y5≈35.8b
[DCF] Fair Price = 235.8 (EV 539b - Net Debt 111b = Equity 428b / Shares 1.82b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 12.42 | EPS CAGR: 10.52% | SUE: N/A | # QB: 0
Revenue Correlation: 14.39 | Revenue CAGR: 6.41% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=61.63 | Chg30d=+27.22% | Revisions=+25% | GrowthEPS=+19.9% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=27.53 | Chg30d=+2.00% | Revisions=+25% | GrowthEPS=-55.3% | GrowthRev=+0.5%